[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652937":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":11,"responsibleParty":36,"collaborators":11,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":11,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":11},{"fullName":5,"class":6},"Women and Infants Hospital of Rhode Island","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"EMLA (lidocaine-prilocaine) Cream","EXPERIMENTAL",null,[13],"Drug: Lidocaine-Prilocaine Cream 2.5-2.5%",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo (compounding, inactive cream)","PLACEBO_COMPARATOR",[18],"Other: Permeation-enhancing vanishing cream",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Lidocaine-Prilocaine Cream 2.5-2.5%","This is the intervention cream. If randomized to this arm, 5 grams will be applied along the planned distribution of TPI approximately 10 minutes prior to the procedure.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Permeation-enhancing vanishing cream","This is the placebo cream. If randomized to this arm, 5 grams will be applied along the planned distribution of TPI approximately 10 minutes prior to the procedure.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Kathryn Kurchena, MD","CONTACT","401-274-1122","48767","KKurchena@wihri.org",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Kathryn Kurchena","Urogynecology and Reconstructive Pelvic Surgery Fellow","100652937","phase-4-lidocaine-prilocaine-cream-as-analgesia-for-in-office-levator-muscle-trigger-point-injections-100652937",false,"NCT07778043","Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections","Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections: a Pilot Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* Patients 18 years or older\n* Patients who are undergoing in-office levator muscle trigger point injection for myofascial pelvic pain\n* Able to give informed consent for the study\n\nExclusion Criteria:\n\n* Documented allergy to lidocaine or prilocaine\n* Use of lidocaine or prilocaine within last 72 hours","FEMALE","18 Years",{"count":50,"type":51},36,"ESTIMATED","INTERVENTIONAL",[54],"PHASE4","Levator muscle trigger point injections (TPI) are a commonly performed procedure in the office for treatment of pelvic pain related to pelvic floor muscles. The most common concern related to in-office TPI is pain. Currently, there is limited information about which medications could reduce pain during TPI. Pain control during in-office gynecologic procedures is a very important topic, and doctors are researching possible options for pain control during these procedures. Lidocaine-prilocaine cream is U.S Food and Drug Administration (FDA) approved for use on the genital area as pretreatment for procedures involving needles. The purpose of this study is to assess if vaginal lidocaine-prilocaine cream reduces pain with TPI compared to a placebo cream.",[57,58],"Myofacial Pain","Pelvic Pain","NOT_YET_RECRUITING","2026-08-18",{"date":62,"type":63},"2026-08-21","ACTUAL",{"date":65,"type":51},"2026-08-17",{"date":67,"type":51},"2028-07",{"name":5,"class":6}]